Document Detail


Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
MedLine Citation:
PMID:  3315586     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ten patients with symptoms of acute myocardial infarction of less than 6 hours duration were randomised to receive either anisoylated plasminogen streptokinase activator complex [APSAC] (30U) or streptokinase (1,500,000U) intravenously. The aims of the study were to compare the angiographic patency of the infarct-related coronary arteries and to monitor drug safety and tolerance for up to 24 hours. The left anterior descending artery was occluded in 3, the left circumflex in 3 and right coronary artery in 4 patients. Time between onset of pain and treatment ranged from 150 to 330 minutes. At 90 minutes, 8 patients, 3 of 5 (60%) of the APSAC group and all of the streptokinase group, had patent arteries. No significant differences were found in measurements of coagulation. There were no haemorrhagic complications. One patient of the APSAC group had reinfarction 6 hours after treatment and died in cardiogenic shock. APSAC seems safe and is easier to use than streptokinase, and both agents result in patency in the majority of patients, although too few patients were included to allow a valid comparison. However, thrombolysis should be considered only a temporary solution in acute myocardial infarction, associated mainly with 3-vessel disease.
Authors:
R Seabra-Gomes; J Aniceto Silva; A Aleixo; T Real; I Freire; I Torres; R Freitas; F Crespo
Related Documents :
2494246 - Quantitative radionuclide assessment of regional ventricular function after thrombolyti...
12204726 - Intrapericardial fibrinolytic therapy in purulent pericarditis.
9085336 - Diffuse pulmonary hemorrhage after streptokinase administration for acute myocardial in...
661356 - Myocardial protection during ischemic cardiac arrest. the importance of magnesium in ca...
3356076 - Pathomorphological changes in experimentally induced canine myocardial infarction.
17332426 - Tetralogy of fallot and alterations in vascular endothelial growth factor-a signaling a...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Drugs     Volume:  33 Suppl 3     ISSN:  0012-6667     ISO Abbreviation:  Drugs     Publication Date:  1987  
Date Detail:
Created Date:  1988-01-07     Completed Date:  1988-01-07     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7600076     Medline TA:  Drugs     Country:  NEW ZEALAND    
Other Details:
Languages:  eng     Pagination:  169-74     Citation Subset:  IM    
Affiliation:
Hospital de Santa Cruz, Carnaxide.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anistreplase
Coronary Angiography
Creatine Kinase / blood
Electrocardiography
Female
Fibrinogen / metabolism
Fibrinolytic Agents / therapeutic use*
Humans
Infusions, Intravenous
Injections, Intravenous
Male
Middle Aged
Myocardial Infarction / blood,  drug therapy*
Plasminogen / metabolism,  therapeutic use*
Random Allocation
Streptokinase / therapeutic use*
Vascular Patency / drug effects
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 81669-57-0/Anistreplase; 9001-32-5/Fibrinogen; 9001-91-6/Plasminogen; EC 2.7.3.2/Creatine Kinase; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.
Next Document:  Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial inf...